Lys142

Site Information
AIsEMTDkLGLQsLR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 15384719

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 )
Disease tissue studied:	colorectal cancer ( 5 ) , colorectal carcinoma ( 5 )
Relevant cell line - cell type - tissue:	HCT116 (intestinal) ( 5 ) , HEK293T (epithelial) ( 4 ) , HEp-2 (squamous) ( 1 ) , MV4-11 (macrophage) ( 4 )

References
1	Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640 29967540 Curated Info
2	Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171 29079793 Curated Info
3	Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40 21906983 Curated Info
4	Wagner SA, et al. (2011) A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory Roles. Mol Cell Proteomics 10, M111.013284 21890473 Curated Info
5	Possemato A (2010) CST Curation Set: 9656; Year: 2010; Biosample/Treatment: cell line, HCT 116/MG132; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info